Showing 1 - 10 of 38
Persistent link: https://www.econbiz.de/10001645077
Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed. For these programs to spur research, potential vaccine developers must believe that the sponsor will not...
Persistent link: https://www.econbiz.de/10012471044
Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to...
Persistent link: https://www.econbiz.de/10012471045
Persistent link: https://www.econbiz.de/10001484287
Persistent link: https://www.econbiz.de/10001768174
Advocates of teacher incentive programs argue that they can strengthen weak incentives, while opponents argue they lead to teaching to the test.' We find evidence that existing teacher incentives in Kenya are indeed weak, with teachers absent 20% of the time. We then report on a randomized...
Persistent link: https://www.econbiz.de/10013038473
We summarize evidence from the growing body of randomized evaluations on health in developing countries from the perspective of the human capital investment model, cost-effectiveness analysis, and behavioral economics. Many cost-effective methods of infectious disease prevention have limited...
Persistent link: https://www.econbiz.de/10014025584
Persistent link: https://www.econbiz.de/10014427662
Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed. For these programs to spur research, potential vaccine developers must believe that the sponsor will not...
Persistent link: https://www.econbiz.de/10013249143
Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to...
Persistent link: https://www.econbiz.de/10013217594